Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Schizoaffective Disorder AND Schizophrenia AND Risperidone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Schizoaffective Disorder AND Schizophrenia AND Risperidone. Displaying page 1 of 1.
    EudraCT Number: 2004-000830-35 Sponsor Protocol Number: RIS-SCH-3007 Start Date*: 2004-07-23
    Sponsor Name:JANSSEN-CILAG
    Full Title: Maintenance of the clinical response with long-acting injectable Risperidone in patients with Schizophrenia or schizoaffective disorders
    Medical condition: Schizophrenia or schizoaffective disorder
    Disease: Version SOC Term Classification Code Term Level
    6.1 10039621 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004494-81 Sponsor Protocol Number: PNB02-C201 Start Date*: 2012-03-29
    Sponsor Name:Pharmaneuroboost N.V.
    Full Title: Proof-of-Concept Study of Pipamperone 15mg added to Stable Treatment with Risperidone or Paliperidone in Chronic Schizophrenic and Schizoaffective Patients with Residual Symptoms: a phase I/IIa, r...
    Medical condition: Schizophrenia or Schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-R criteria.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10009134 Chronic schizophrenia LLT
    14.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004246-32 Sponsor Protocol Number: D1443L00031 Start Date*: 2007-12-05
    Sponsor Name:ASTRAZENECA
    Full Title: Comparison of Quetiapine Extended-Release (Seroquel XR™ ) and Risperidone in the treatment of depressive symptoms, in schizophrenic or schizoaffective patients: A randomized, open label, flexible-d...
    Medical condition: Patient with schizophrenia or schizoaffective disorder with depressive symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039620 Schizoaffective and schizophreniform disorders HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004752-16 Sponsor Protocol Number: BP40283 Start Date*: 2021-07-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF RO6889450 (RALMITARONT) IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AND NEGATIVE SYMPTOMS
    Medical condition: Schizophrenia or schizoaffective disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000338-37 Sponsor Protocol Number: 1723/1-1 Start Date*: 2014-11-04
    Sponsor Name:Technische Universität München, vertreten durch das Klinikum rechts der Isar
    Full Title: Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal...
    Medical condition: schizophrenia or schizoaffective disorder in remission for at least 3 years under a stable antipsychotic medication.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    17.0 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000870-29 Sponsor Protocol Number: RISSCH3001 Start Date*: 2004-11-04
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness
    Medical condition: SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) SE (Completed) CZ (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004621-25 Sponsor Protocol Number: RIS-SCH-4043 Start Date*: 2006-01-30
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta?
    Medical condition: Schizophrenia, schizoaffective disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039613 Schizo-affective type schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003623-23 Sponsor Protocol Number: can.clo.ris.fMRI Start Date*: 2008-09-17
    Sponsor Name:Academisch medisch centrum, department of psychiatry
    Full Title: Effect of different antipsychotic medication on craving related brain activity in patients with schizophrenia and cannabis abuse or dependence: a randomized controlled study comparing clozapine and...
    Medical condition: A randomized controlled trial comparing the effect of clozapine and risperidone on cannabis craving in cannabis abusing or dependent patients with schizophrenia. Specific cognitive tasks will be us...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004602-17 Sponsor Protocol Number: 031-201-00186 Start Date*: 2018-03-12
    Sponsor Name:Otsuka Pharmaceutical
    Full Title: A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizo...
    Medical condition: Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000053-27 Sponsor Protocol Number: MELIA Start Date*: 2020-07-09
    Sponsor Name:UMC Utrecht
    Full Title: The MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain.
    Medical condition: Antipsychotic-induced weight gain (AiWG)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004740-79 Sponsor Protocol Number: D1443L00039 Start Date*: 2008-06-10
    Sponsor Name:AstraZeneca GmbH
    Full Title: A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated with Quetiapine XR (SEROQUEL Prolong®) or Oral Risperidone at Flexible D...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed) PT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-006048-42 Sponsor Protocol Number: P04628 Start Date*: 2006-09-05
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Phase 2a, Multiple-Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti-Psychotic-Induced Extra-Pyramidal Symptoms Among Subjects Wi...
    Medical condition: Patients with schizophrenia and schizoaffective disorders experiencing anti-psychotic-induced extra-pyramidal symptoms.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003834-21 Sponsor Protocol Number: 80-83600-98-10086 Start Date*: 2016-09-23
    Sponsor Name:Erasmus Medical Center Rotterdam
    Full Title: Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial.
    Medical condition: Psychotic disorders
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004972-11 Sponsor Protocol Number: S154.3.020 Start Date*: 2007-04-11
    Sponsor Name:Solvay Pharmaceuticals Inc
    Full Title: A multi-center, open-label, parallel-group, randomized, flexible dose study to evaluate the safety and tolerability of switching from existing atypical antipsychotics to bifeprunox in subjects with...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005773-63 Sponsor Protocol Number: D1443L00042 Start Date*: 2008-03-27
    Sponsor Name:AstraZeneca Oy
    Full Title: A Pilot Study of Three-Weeks, Randomized, Prospective, Open Comparison in Schizophrenic In-patients Treated with Quetiapine Prolong or Oral Risperidone at Flexible Dose
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-000016-27 Sponsor Protocol Number: CL2-33138-007 Start Date*: 2005-05-09
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    3. SERVIER Research and Development ICTR (For United Kingdom only)
    Full Title: Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-gro...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10039626 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001582-12 Sponsor Protocol Number: 4 Start Date*: 2023-03-01
    Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red (CIBER)
    Full Title: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode.
    Medical condition: First episode SZ-spectrum individuals
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002304-41 Sponsor Protocol Number: RIS-SCH-4045 Start Date*: 2005-09-23
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia or schizoaffective disorder after an acute episode
    Medical condition: Schizophrenia or schizoaffective disorder.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) GB (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005399-16 Sponsor Protocol Number: ROAC2014 Start Date*: 2014-08-05
    Sponsor Name:Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL
    Full Title: Randomized, flexible-dose, open-label comparison to investigate the effectivenes of second generation antipsychotics in first episode psychosis patients.
    Medical condition: FIRST EPISODE DRUG-NAÏVE OF PSYCHOSIS (SCHIZOPHRENIA SPECTRUM DISORDERS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004893-84 Sponsor Protocol Number: CBD-P Start Date*: 2019-08-22
    Sponsor Name:Mental Health Center Glostrup
    Full Title: Cannabidiol for treatment of non-affective psychosis and cannabis use
    Medical condition: Non-affective psychosis and lifetime cannabis use
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10037234 Psychosis LLT
    21.1 100000004869 10070996 Cannabis use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 07:43:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA